BridgeBio Pharma, Inc. (BBIO) Q1 FY26 Earnings Call

Q1 FY26 results, source: company transcript and SEC filings
QuarterQ1 FY26
Length53 minutes
EPS$-0.84
EPS consensus$-0.70
Revenue$194.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All BBIO earnings ยท Back to BBIO overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.